Related resources
Full-text held externally
- DOI: 10.1002/acr.21747
- PMID: 22674853
- UKPMCID: 22674853
Search for item elsewhere
University researcher(s)
Academic department(s)
Minimal clinically important improvement and patient acceptable symptomatic state in pain and function in rheumatoid arthritis, ankylosing spondylitis, chronic back pain, hand osteoarthritis, and hip and knee osteoarthritis: The reflect multinational study.
Tubach, F; Ravaud, P; Martin-Mola, E; Awada, H; Bellamy, N; Bombardier, C; Felson, Dt; Hassouni, N; Hochberg, M; Logeart, I; Matucci-Cerinic, M; van de Laar, M; van der Heijde, D; Dougados, M
Arthritis care & research. 2012;64(11):1699-1707.
Access to files
Full-text and supplementary files are not available from Manchester eScholar. Full-text is available externally using the following links:
Full-text held externally
- DOI: 10.1002/acr.21747
- PMID: 22674853
- UKPMCID: 22674853
Abstract
OBJECTIVE: To estimate the Minimum Clinically Important Improvement (MCII) and Patient Acceptable Symptomatic State (PASS) values for 4 generic outcomes in 5 rheumatic diseases and 7 countries. METHODS: We conducted a multinational (Australia, France, Italy, Lebanon, Morocco, Spain, The Netherlands), 4-week cohort study involving 1,532 patients which were prescribed NSAISDs for ankylosing spondylitis, chronic back pain, hand osteoarthritis, hip and/or knee osteoarthritis or rheumatoid arthritis. The MCII and PASS values were estimated with the 75(th) percentile approach for 4 generic outcomes: pain, patient global assessment, functional disability and physician global assessment, all normalized to a 0-100 score. RESULTSA: For the whole sample, the estimated MCII values for absolute change at 4 weeks (95% confidence interval [95% CI]) were -17 (-18, -15) for pain; -15 (-16, -14) for patient global assessment; -12 (-13, -11) for functional disability assessment; and -14 (-15, -14) for physician global assessment. For the whole sample, the estimated PASS values were 42 (40, 44) for pain; 43 (41, 45) for patient global assessment; 43 (41, 44) for functional disability assessment; and 39 (37, 40) for physician global assessment. Estimates were consistent across diseases and countries (for subgroups ≥20 patients). CONCLUSION: This work allows for promoting the use of values of MCII (15/100 for absolute improvement, 20% for relative improvement) and PASS (40/100) in reporting the results of trials of any of the 5 involved rheumatic diseases with pain, patient global assessment, physical function or physician global assessment used as outcome criteria. © 2012 by the American College of Rheumatology.